Specific tumor lysis

There are many strategies being employed in cancer immune therapy. Whether you’re focused on antibodies, cell based therapies or checkpoint inhibitors, in the end, the goal is the same: killing tumor cells!

Autologous cell tumor cell lines can be generated to study patient specific effects.

References

King LA, Toffoli EC, Veth M, Iglesias-Guimarais V, Slot MC, Amsen D, van de Ven R, Derks S, Fransen MF, Tuynman JB, Riedl T, Roovers RC, Adang AEP, Ruben JM, Parren PWHI, de Gruijl TD, van der Vliet HJ. A Bispecific γδ T-cell Engager Targeting EGFR Activates a Potent Vγ9Vδ2 T cell-Mediated Immune Response against EGFR-Expressing Tumors. Cancer Immunol Res. 2023 Sep 1;11(9):1237-1252. doi: 10.1158/2326-6066.CIR-23-0189. PMID: 37368791.

Veluchamy JP, Heeren AM, Spanholtz J, van Eendenburg JD, Heideman DA, Kenter GG, Verheul HM, van der Vliet HJ, Jordanova ES, de Gruijl TD. High-efficiency lysis of cervical cancer by allogeneic NK cells derived from umbilical cord progenitors is independent of HLA status. Cancer Immunol Immunother. 2017 Jan;66(1):51-61. doi: 10.1007/s00262-016-1919-1. Epub 2016 Oct 25. PMID: 27783105; PMCID: PMC5222919.